A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/21/2019
Start Date:March 10, 2014
End Date:December 31, 2021
Contact:There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone:1-317-615-4559

Use our guide to learn which trials are right for you!

A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer

This study evaluates the safety of abemaciclib in combination therapies (letrozole,
anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus
fulvestrant, pertuzumab plus trastuzumab with loperamide) for breast cancer that has spread
to other parts of the body.


Inclusion Criteria:

- Have a diagnosis of hormone receptor positive (HR+), human epidermal growth factor
receptor 2 (HER2) negative metastatic breast cancer for Parts A to E, G, and I.

- Have a diagnosis of human epidermal growth factor receptor 2 (HER2) positive
metastatic breast cancer for Parts F and H.

- For Part A (LY2835219 + letrozole): Except for ongoing therapy with letrozole, the
participant must not have received prior systemic endocrine therapy for metastatic
disease.

- For Part B (LY2835219 + anastrozole): Except for ongoing therapy with anastrozole, the
participant must not have received prior systemic endocrine therapy for metastatic
disease.

- For Part C (LY2835219 + tamoxifen): The participant may have received prior systemic
endocrine therapy for metastatic disease and may be receiving ongoing therapy with
tamoxifen.

- For Part D (LY2835219 + exemestane): The participant must have received prior systemic
endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole,
letrozole) for metastatic disease and may be receiving ongoing therapy with
exemestane.

- For Part E (LY2835219 + exemestane + everolimus): The participant must have received
prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor
(anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy
with either exemestane or exemestane + everolimus.

- For Part F (LY2835219 + trastuzumab):The participant must have received at least 1
chemotherapy regimen for metastatic disease and may be receiving ongoing therapy with
trastuzumab. The participant must have an estimated left ventricular ejection fraction
within the normal range by either echocardiogram or multigated acquisition (MUGA) scan

- For Part G (abemaciclib + LY3023414 + fulvestrant): The participant may have received
prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor
(anastrozole, letrozole) for metastatic disease.

- For Part H: (abemaciclib + trastuzumab + pertuzumab): The participant must have
received at least 1 chemotherapy regimen for metastatic disease. The participant may
be receiving ongoing therapy with trastuzumab and/or pertuzumab at the time of study
entry. The participant must have an estimated left ventricular ejection fraction
(LVEF) within the normal range by either echocardiogram or multigated acquisition
(MUGA) scan.

- For Part I (abemaciclib + endocrine therapy): The participant must have demonstrated
evidence of disease progression on a Cyclin Dependent Kinase 4 (CDK4) and Cyclin
Dependent Kinase 6 (CDK6) inhibitor (either palbociclib or ribociclib) plus endocrine
therapy for advanced or metastatic disease as the most recent therapy immediately
preceding study entry. The participant should remain on the current endocrine therapy
while receiving abemaciclib.

- For Parts A, B, C, D, E, and F: Have either measureable disease or nonmeasureable but
evaluable bone disease as defined by the Response Evaluation Criteria in Solid Tumors
(RECIST 1.1)

- For Part G, H, and I: Have measureable disease as defined by RECIST 1.1.

- For all Parts except Part F and H: Participants must have either post-menopausal
status or pre-menopausal status if continuing or beginning ovarian suppression with a
luteinizing hormone-releasing hormone (LHRH) agonist such as goserelin.

- Parts H, and I: Must be able and willing to undergo mandatory tumor biopsies prior to
study treatment and at the time of discontinuation from study treatment.

- Have adequate organ function, including:

- Hematologic: Absolute neutrophil count (ANC) ≥1.5 x 10^9/liter (L), platelets ≥
100 x 10^9/L, and hemoglobin ≥ 8 gram/deciliter (g/dL).

- Hepatic: Bilirubin ≤1.5 times upper limits of normal (ULN), alanine
aminotransferase (ALT) ≤ 3.0 times ULN.

- Renal: Serum creatinine ≤ 1.5 times ULN.

- Have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG)
scale.

- Have discontinued all previous therapies for breast cancer (including chemotherapy,
radiotherapy, immunotherapy, and investigational therapy), except for ongoing
corresponding combination therapy, for at least 21 days for myelosuppressive agents or
14 days for nonmyelosuppressive agents prior to receiving study drug(s), and recovered
from the acute effects of therapy (until the toxicity resolves to either baseline or
at least Grade 1) except for residual alopecia or peripheral neuropathy. For Part F
and H: concurrent treatment with trastuzumab emtansine (T-DM1) is not allowed.

Exclusion Criteria:

- Have metastatic breast cancer with severe organ dysfunction as assessed by symptoms
and signs, laboratory studies, and rapid progression of the disease.

- Have brain metastasis without prior radiotherapy.

- For Parts A, B, C, D, E, G and I: Have received prior systemic chemotherapy for
metastatic disease. However, the participant may have received prior systemic
chemotherapy in the neoadjuvant or adjuvant setting.

- For Parts A, B, C, D, E, F, H: Have received prior therapy with a CDK4/6 inhibitor,
Part G: Have received prior therapy with fulvestrant or any PI3K and/or mTOR inhibitor
(including LY3023414); Part I: Have received prior treatment with abemaciclib in any
setting.

- Have serious preexisting medical conditions that, in the judgment of the investigator,
would preclude participation in this study (for example, history of major surgical
resection involving the stomach or small bowel).

- Have central nervous system (CNS) metastasis with either radiotherapy or development
of neurological changes ≤14 days prior to receiving study treatment. Participants may
be receiving a stable dose of corticosteroids. Screening of asymptomatic participants
without history of CNS metastasis is not required. Untreated CNS metastases are not
permitted.

- For Parts F and H: Cardiac disease including myocardial infarction within 6 months,
unstable angina, or New York Heart Association (NYHA) Grade II or greater functional
impairment.

- For Part G: Have type 1 diabetes mellitus or a history of gestational diabetes
mellitus. Participants with a type 2 diabetes mellitus are eligible if adequate
control of blood glucose level is obtained with oral therapy as documented by
Hemoglobin A1c <7%.

- For Part G: Have a baseline electrocardiogram (obtained from Day -14 to Day -1) with
any of the following abnormal findings: ventricular arrhythmia, evidence of acute
myocardial ischemia, heart block (of any degree), or QTc prolongation (defined as QTcB
≥450 milliseconds).
We found this trial at
16
sites
9500 Gilman Dr
La Jolla, California 92093
(858) 534-2230
Principal Investigator: Teresa Helsten
Phone: 858-246-4777
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: E. Claire Dees
Phone: 919-843-7714
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Brent N Rexer
Phone: 615-936-3524
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Sara M Tolaney
Phone: 617-632-5869
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Carlos H Becerra
Phone: 214-370-1949
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
Principal Investigator: Joseph T Beck
Phone: 479-587-1700
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Principal Investigator: Howard A. Burris III
Phone: 615-329-7274
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
230 25th Ave N
Nashville, Tennessee 37203
(615) 329-7274
Principal Investigator: SMO Sarah Cannon Research Inst.
Phone: 615-327-7212
Sarah Cannon Cancer Center People who live with cancer
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Kevin Kalinsky
Phone: 212-305-1945
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Komal Jhaveri
Phone: 646-888-5145
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Oklahoma City, Ohio 73104
Principal Investigator: Kathleen Moore
Phone: 4052717770
?
mi
from
Oklahoma City, OH
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Shannon L Huggins-Puhalla
Phone: 412-641-3494
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Portland, Oregon 97213
Principal Investigator: Alison Conlin
Phone: 506-216-8636
?
mi
from
Portland, OR
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Matthew P Goetz
Phone: 507-266-6264
?
mi
from
Rochester, MN
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Muralidhar Beeram
Phone: 210-593-5250
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Woodlands, Texas 77380
?
mi
from
The Woodlands, TX
Click here to add this to my saved trials